fifty-one valuable patients with malignant sarcomas were randomly allocated to receive three courses of remission induction chemotherapy with cyclophosphamide , vincristine , adriamycin , and dimethyl triazeno imidazole carboxamide ( cyvadic ) on the protected environment-prophylactic antibiotic for the control group ( p = 0.22 ) .
C0010583
cyclophosphamide
C0057010
cyvadic